Alkem Lab Financial Statements

Alkem Lab (ALKEM) reported revenue of ₹134.58B in FY2025 with net income of ₹22.15B. Total assets stood at ₹176.91B and free cash flow was ₹16.89B.

Alkem Lab Income Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Revenue		90.98B	107.97B	118.15B	129.78B	134.58B
Cost of Rev. Cost of Revenue		-34.98B	-41.80B	-49.07B	-49.38B	-47.64B
Gross Profit		56.00B	66.17B	69.09B	80.41B	86.94B
SGA Sales, General & Admin		-34.24B	-44.01B	-50.83B	-54.85B	-56.88B
Op. Income Operating Income		19.01B	19.12B	15.15B	22.57B	26.49B
PBT Profit Before Tax		18.42B	18.44B	13.05B	20.23B	25.26B
Net Income		15.85B	16.80B	10.07B	18.11B	22.15B
Dil. Shares Diluted Shares		119.57M	119.57M	119.57M	119.57M	119.57M
Diluted EPS		132.57	137.63	82.31	150.19	181.11

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Alkem Lab's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Alkem Lab Balance Sheet

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Curr. assets Total current assets		69.23B	84.34B	86.06B	104.12B	108.11B
Non-curr. assets Total non-current assets		45.96B	56.35B	51.50B	51.63B	68.80B
Total assets		115.19B	140.69B	137.57B	155.75B	176.91B
Curr. liabilities Total current liabilities		36.04B	48.05B	37.07B	39.95B	39.65B
Non-curr. liab. Total non-current liabilities		3.57B	4.17B	6.15B	8.66B	12.92B
Total liabilities		39.61B	52.22B	43.22B	48.61B	52.57B
Total equity		75.58B	88.47B	94.35B	107.14B	124.34B
Total liab. & eq. Total liabilities & equity		115.19B	140.69B	137.57B	155.75B	176.91B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Alkem Lab's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Alkem Lab Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2019 – FY 2024

Item	Chart	2019	2020	2021	2022	2024
Net Income		9.55B	12.60B	18.42B	18.44B	20.23B
Operating CF Cash flow Operating Activities		7.77B	5.85B	12.65B	11.11B	19.48B
Capex Investments in PPE		-5.29B	-3.63B	-1.95B	-3.39B	-2.59B
Investing CF Cash flow Investing Activities		-3.14B	-7.41B	-9.99B	-14.35B	-10.09B
Dividend Paid		-2.19B	-4.40B	-3.35B	-4.22B	-5.40B
Financing CF Cash flow Financing Activities		-3.79B	791.50M	-2.72B	3.80B	-11.45B
Cash (start) Cash at beginning of period		1.67B	2.49B	1.76B	1.74B	2.74B
Cash (end) Cash at end of period		2.49B	1.76B	1.74B	2.32B	663.10M
FCF Free Cash Flow		2.48B	2.22B	10.70B	7.72B	16.89B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Alkem Lab's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025